Ark Biosciences Reports Successful Completion of Phase II Proof-of-Concept Clinical Trial of Ziresovir for Treatment of Infants Hospitalized with Respiratory Syncytial Virus (RSV) Infection
know more >
Ark Biosciences to present at JPM Healthcare Conference in San Francisco
know more >
Ark Biosciences Reports Significant Progress of Phase 2 Clinical Trial of Ziresovir for Treatment of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients
know more >
Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
Ark to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018...
know more >
Ark Biosciences Licenses a Clinical Stage Drug for Treatment of Idiopathic Pulmonary Fibrosis
Ark announced a license agreement for a Roche's potential drug for idiopathic pulmonary fibrosis...
know more >